Disc Medicine, Inc.

Disc Medicine, Inc., trading under the ticker GMTX, is a clinical-stage biopharmaceutical company focused on hematology and the treatment of serious blood diseases through heme biology. The company filed an 8-K with the SEC on December 29, 2022, accession number 0001140361-22-047453, marking a significant corporate milestone in its transition from Gemini Therapeutics — which originally reached public markets through a SPAC business combination with LifeSci Acquisition Corp., sponsored by LifeSci Capital — and its subsequent rebranding and strategic pivot toward hematologic disorders. The company operates within the healthcare and life sciences sector. Visit SpacDesk and sign up for full access to filing timelines, sponsor profiles, and deal analytics on this and hundreds of other SPAC transactions.